Ilya Pharma will attend Jefferies Health Care Conference in London 15-16 Nov
News
Ilya Pharma will present company updates at BioFuture hosted live in NYC 7-8 November and virtually 14-16 November
Conference topic is to - Reimagine the future of therapeutics
Ilya Pharma appoints Leo Groenewegen as CEO of recent acquisition Nordic Bioanalysis
Bioprocessing and analytics industry business expert to spearhead major growth drive
Ilya Pharma presents poster at US Military Health System Research Symposium in Florida September 12
Dr Andreas Fasth, Head of Clinical Developments and Medical Affairs at Ilya Pharma is on site and presenting "Accelerated wound healing by on-site production and delivery of CXCL12 by transformed lactic acid bacteria in 36 healthy volunteers with experimentally induced wounds".
Labiotech.eu reports on Ilya Pharmas latest new patents covering major markets
Ilya Pharma, a Swedish clinical stage biopharma company focused on delivering local immunotherapies to patients, has announced the issue of four new patents.
Ilya Pharma present at BIO San Diego 13-16 June
The 2022 BIO International Convention will feature 100+ interactive sessions across 4 days covering a variety of therapeutic areas, business development, digital health, patient advocacy, public policy, and next-generation biotherapeutics, and the latest updates from industry experts on COVID-19 and the vaccine.
Ilya Pharma makes strategic investment in bioanalytical company
Ilya Pharma has made a strategic investment in its supply chain to facilitate development of its ILP pipeline by acquiring one of its long-term partners, Nordic Bioanalysis.
8.5 MEUR to advance our three programs
Ilya Pharma has closed a 8.5 million EUR funding round where the EIC Fund participated and was joined by an international consortium of family offices and private investors